COCP Cocrystal Pharma, Inc. Insider Trading

Director Frost Phillip MD bought 20,000 COCP shares at $1.00 on 2026-02-24; holding now 1.91M shares amid revenue collapse and ongoing losses.

Frost Phillip MD, a director of Cocrystal Pharma, purchased 20,000 shares at $1.00 on 2026-02-24, adding to a holding of 1.91M shares post-transaction. This purchase is notable in the context of severe fundamental deterioration: the company posted revenue of $489,000.00 in its latest quarter, net income of $-2,049,000.00, and year-over-year revenue growth of -69.3%, while remaining unprofitable over its most recent full fiscal year. The stock is currently trading at $1.04, down 46.9% from its 52-week high of $1.96. Frost has executed five prior purchases at this ticker (all within the past two months: 2025-12-24, 2025-12-26, 2025-12-30, 2025-12-31, and 2026-02-06), with measurable 30-day outcomes ranging from +3.6% to +7.2% on the four earliest trades, yet his cross-ticker buy track record shows an average 90-day return of -6.4% and a 90-day win rate of only 13.33%. The repeated accumulation at a depressed valuation amid operational decline presents a divergence between the director's frequent open-market acquisitions and the company's deteriorating financial trajectory.

Director Frost buys 50,000 COCP shares at $0.95; stock down 58.3% from 52-week high amid -69.3% revenue decline

Phillip Frost purchased 50,000 shares at $0.95, expanding his COCP holdings from 1,838,551 to 1,888,551 shares—a 2.7% increase in his position. This marks the sixth consecutive purchase at COCP within 11 weeks (five prior trades between 2025-11-26 and 2025-12-31). The current stock price of $0.95 stands 58.3% below the 52-week high and has declined 16.7% over the past 30 days, reflecting a deteriorating market backdrop. COCP fundamentals show acute distress: annual revenue contracted 69.3% year-over-year to $489,000, the company posted a $2.0M net loss in the latest quarter, and market capitalization stands at only $13.1M. Frost's prior COCP purchases, though limited in measurable outcomes due to recent timing, show mixed near-term results (range: -2.8% to +7.2% at 30 days); none yet demonstrate positive 90-day returns. The repetitive buying pattern into sharply declining fundamentals and depressed share price warrants scrutiny of whether Frost possesses non-public information about stabilization or strategic developments at the company.

Director Frost buys 50,000 COCP shares at $0.95 amid -69.3% annual revenue decline and $-2.0M net loss.

Phillip Frost purchased 50,000 shares at $0.95 on 2025-12-31, bringing his holdings to 1,838,551 shares, on the heels of three consecutive buy days (2025-12-24, 2025-12-26, 2025-12-30). This buying activity occurs at $0.99 current price, -69.5% below the 52-week high of $3.25, and during a period of severe operational stress: annual revenue declined -69.3% to $489,000.00 and the company reported a net loss of $-2.0M over its most recent fiscal year. His cross-ticker track record shows 20 prior buys with an average 30-day return of -1.2%, and same-ticker outcomes at COCP are mixed, with recent 30-day returns of -2.8% and -1.8% on his prior November purchases. The timing of these sequential purchases during a sharp drawdown and amid fundamental deterioration—without measurable 90-day outcomes from any of his same-ticker trades—suggests sustained accumulation at depressed prices rather than confidence validated by historical execution.

Frost buys 20,000 shares of COCP at $0.97; director accumulating in distressed biotech -69.8% from 52-week high.

Frost purchased 20,000 shares at $0.97 on 2025-12-30, increasing holdings to 1,788,551 shares post-transaction. This represents a continuation of recent activity: Frost has executed three additional open-market purchases at COCP in the prior four days (2025-12-31, 2025-12-26, 2025-12-24), suggesting sustained accumulation despite significant price deterioration. The stock is -69.8% from its 52-week high of $3.25 and -4.8% over the trailing 30 days, reflecting material decline in shareholder value. COCP's fundamentals are severely compromised: the company reported quarterly revenue of $489,000.00 and net loss of $-2,049,000.00, with annual revenue declining -69.3% year-over-year and an unprofitable full-year result. Frost's cross-ticker track record shows 20 prior open-market buys with an average 30-day return of -0.6%, indicating limited success at timing market entry points. At COCP specifically, prior buy-side trades have not shown positive 90-day returns in measurable outcomes (0 of 0 well-timed at the 90-day mark). The transaction reveals a director's discretionary accumulation in a financially deteriorating company during a period of steep stock decline, without supporting evidence of successful market timing from historical activity.

Director Frost Phillip purchased 65,000 shares (65.0K shares) at $0.97 across 2 transactions, adding 3.8% to holdings.

Frost Phillip (Director) executed 2 separate purchases totaling 65,000 shares for $63,201.50 at a blended average price of $0.97 on consecutive trading days (2025-12-24 and 2025-12-26). The current price of $0.98 sits -69.8% from the 52-week high of $3.25, and the stock has declined -21.6% over the past 90 days. At the company level, Cocrystal Pharma reported net income of -$2,049,000.00 in the latest quarter and annual revenue contraction of -69.3%, with a market cap of $13,508,383.70. Phillip's prior trades at this ticker show mixed near-term outcomes: one prior buy returned +3.6% over 30 days, while two others returned -1.8% and -2.8%, and his cross-ticker track record across 20 prior buys averaged -0.2% over 30 days, with no evidence of consistent well-timed purchases at the 90-day mark.

Frost purchases 4,000 COCP shares in 2 transactions at $0.99–$1.00 (Nov 26); stock now at $1.06, down 67.4% from 52-week high.

Frost, a director at Cocrystal Pharma, executed 2 separate purchases totaling 4,000 shares for $3,975.00 at a blended average price of $0.99 on November 26, 2025. The timing follows a purchase the prior day (November 25) and occurs at prices near the bottom of the 52-week range ($0.90–$3.25), where the stock is currently trading at $1.06—down 67.4% from its 52-week high. The company's fundamentals show deteriorating conditions: Q3 2025 revenue of $489,000.00 with a net loss of $-2,049,000.00, annual revenue growth of −69.3%, and an unprofitable fiscal year. While Frost's cross-ticker track record shows 20 prior buys, his prior trades at this ticker remain too recent to evaluate timing outcomes (both November 25 and 26 purchases have insufficient 90-day return data). The incremental position increase of 4,000 shares represents 0.2% of pre-transaction holdings.

Director Frost buys 20,000 COCP shares at $0.94; stock down 71.1% from 52-week high, company posted -69.3% revenue decline.

Director Phillip Frost purchased 20,000 shares of Cocrystal Pharma at $0.94, a continuation of his documented pattern of 20 prior open-market buys across his portfolio. The purchase occurred while the stock trades at 71.1% below its 52-week high of $3.25 and has declined 20.3% over the past 30 days and 39.4% over the past 90 days. This coincides with severe deterioration in the company's fundamentals: revenue contracted 69.3% year-over-year to $489,000 in the latest quarter, and the company reported a net loss of $-2,049,000 over its most recent full fiscal year. With a market cap of $12,957,021.10, the company remains unprofitable. The transaction is characterized by its routine nature relative to Frost's historical pattern, though the steep decline in both price and fundamentals warrants examination of whether this reflects conviction in a turnaround or simply a structural market dynamic.